Nasdaq GlobeNewswire

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year

Del

Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance

DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period.  

Financial and operating highlights during the first quarter of fiscal 2018 include:

  • Fiscal first quarter worldwide revenue from Impella® heart pumps totaled $127.2 million, an increase of 30% compared to revenue of $97.8 million during the same period of the prior fiscal year.  U.S. revenue from Impella heart pumps grew 28% to $114.7 million and U.S. Impella patient usage grew 27%.  
     
  • Outside the U.S., revenue from Impella heart pumps totaled $12.5 million and was up 53%, predominately from Germany, which grew 62% in revenue from the prior fiscal year.
     
  • The installed base for Impella 2.5® heart pumps in the U.S. grew by an additional 16 hospitals, which made initial purchases of Impella heart pumps, bringing the installed customer base to 1,154 sites. The installed customer base for Impella CP® heart pumps grew by 46 new U.S. hospitals, bringing the total number of Impella CP sites to 1,062. The installed customer base for Impella 5.0® heart pumps grew by 19 new U.S. hospitals, bringing the total number of Impella 5.0 sites to 472.
     
  • An additional 15 sites made initial purchases of the Impella RP® heart pumps during the quarter, bringing the total number to 142 sites.
     
  • Gross margin for fiscal first quarter 2018 was 83.5% compared to 85.4% in the first quarter of fiscal 2017. 
     
  • Operating income for the first quarter of fiscal 2018 was $33.1 million, or 25.0% operating margin, compared to $21.2 million, or 20.6% operating margin in the prior year period. 
     
  • First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, which benefited from the adoption of a new accounting standard that required $16.8 million, or $0.37 per diluted share, of excess tax benefits related to employee share-based compensation awards be recorded as a reduction of income tax expense. This compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period, before new accounting standards.
     
  • The Company generated $12.0 million in cash, cash equivalents and marketable securities, totaling $289.1 million as of June 30, 2017, compared to $277.1 million at March 31, 2017. The Company incurs annual cash outlays in the first quarter and currently has no debt.
     
  • The Company has recently received approval from the Japanese Ministry Health Labour and Welfare (MHLW) for reimbursement on Impella 2.5 and 5.0 Impella heart pumps and 10 physician societies have completed the hospital guidance document. At recent average exchange rates, reimbursement in Japan is estimated to be $24,000, equivalent to our Impella sales price in the U.S., and commences this September. We expect our first Japanese patient in September and are reiterating our controlled Impella launch at 10 hospitals by end of this fiscal year in March.
     
  • On June 30, a new study of Abiomed's Impella 2.5 heart pump demonstrated potential survival benefit with pre-PCI insertion in heart attacks with the left main coronary artery.

"We have been notified by MHLW of Japanese reimbursement for Impella beginning in September allowing our introduction into the world's second largest medical device market," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "Our continued execution validates Abiomed as one of the fastest growing medical technology companies with increasing GAAP profitability and no debt. I am proud of our team's ability to consistently achieve our strategic initiatives and execute on our tactical plan as Abiomed builds the Field of Heart Recovery."

FISCAL YEAR 2018 OUTLOOK
The Company is increasing the lower end of its fiscal year 2018 revenue guidance by $5 million to a new range of $560 million to $575 million, an increase in revenue of 26% to 29% from the prior year. This compares to the prior forecast of $555 million to $575 million. The Company is maintaining its fiscal year guidance for GAAP operating margin in the range of 22% to 24%.

CONFERENCE CALL
The Company will host a conference call to discuss the results on Thursday, July 27, 2017, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538.  A replay of this conference call will be available beginning at 11 a.m. EDT July 27, 2017 through 11 a.m. EDT on July 30, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 51159965.

ABOUT ABIOMED 
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS 
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

 
Abiomed, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share data)
         
    June 30, 2017   March 31, 2017
         
ASSETS        
Current assets:        
Cash and cash equivalents   $   43,970     $   39,040  
Short-term marketable securities     207,441         190,908  
Accounts receivable, net        53,557         54,055  
Inventories        36,926         34,931  
Prepaid expenses and other current assets       9,021         8,024  
Total current assets     350,915         326,958  
Long-term marketable securities       37,669         47,143  
Property and equipment, net       92,804         87,777  
Goodwill       33,199         31,045  
In-process research and development       15,487         14,482  
Long-term deferred tax assets, net     113,457         34,723  
Other assets       8,686         8,286  
Total assets   $ 652,217     $   550,414  
LIABILITIES AND STOCKHOLDERS' EQUITY        
Current liabilities:        
Accounts payable   $   12,784     $   20,620  
Accrued expenses       35,695         37,703  
Deferred revenue       9,697         10,495  
Current portion of capital lease obligation       829         799  
Total current liabilities       59,005         69,617  
Other long-term liabilities       588         3,251  
Contingent consideration       9,418         9,153  
Long-term deferred tax liabilities       837         783  
Capital lease obligation, net of current portion       15,325         15,539  
Total liabilities       85,173         98,343  
Commitments and contingencies        
Stockholders' equity:        
Class B Preferred Stock, $.01 par value       -         -  
Authorized - 1,000,000 shares; Issued and outstanding - none        
Common stock, $.01 par value       441         437  
Authorized - 100,000,000 shares; Issued - 45,791,680 shares at June 30, 2017 and 45,249,281 shares at March 31, 2017         
Outstanding - 44,080,941 shares at June 30, 2017 and 43,673,286 shares at March 31, 2017        
Additional paid in capital     580,017         565,962  
Retained earnings (accumulated deficit)       65,661         (46,959 )
Treasury stock at cost - 1,710,739 shares at June 30, 2017  and 1,575,995 shares at March 31, 2017      (64,567 )       (46,763 )
Accumulated other comprehensive loss     (14,508 )       (20,606 )
Total stockholders' equity     567,044         452,071  
Total liabilities and stockholders' equity   $ 652,217     $   550,414  
         

Abiomed, Inc. and Subsidiaries  
Consolidated Statements of Operations  
(Unaudited)  
(in thousands, except per share data)  
             
             
  Three Months Ended 
June 30,
 
  2017     2016    
Revenue:            
Product revenue $   132,431     $   102,989    
Funded research and development     37         6    
      132,468         102,995    
Costs and expenses:            
Cost of product revenue      21,862         15,070    
Research and development      16,931         15,660    
Selling, general and administrative      60,597         51,032    
      99,390         81,762    
Income from operations     33,078         21,233    
Other income:            
Investment income, net     635         269    
Other income (expense), net     79         (77 )  
      714         192    
Income before income taxes     33,792         21,425    
Income tax (benefit) provision (1)     (3,582 )       8,515    
Net income $   37,374     $   12,910    
             
Basic net income per share $   0.85     $   0.30    
Basic weighted average shares outstanding     43,895         42,811    
             
Diluted net income per share (2) $   0.82     $   0.29    
Diluted weighted average shares outstanding     45,608         45,178    
             
             
(1) Income tax provision includes the effect of the following item:            
Excess tax benefits related to stock-based compensation awards * $   16,842     $   -    
             
(2) Diluted net income per share includes the effect of the following item:            
Excess tax benefits related to stock-based compensation awards * $   0.37     $   -    
             
* In the first quarter of fiscal 2018, the Company adopted Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires that all excess tax benefits and tax deficiencies related share-based compensation arrangements be recognized as income tax benefit or expense, instead of in stockholders' equity as previous guidance required.  
             

For further information please contact: 

Ingrid Goldberg Ward
Director, Investor Relations
978-646-1590
ir@abiomed.com

Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith@abiomed.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Algeco Announces Second Quarter 2018 Financial Results Conference Call and Change to Reporting in Euro15.8.2018 18:00Pressemelding

BALTIMORE, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (together with its subsidiaries, “Algeco”), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that it will hold its second quarter 2018 financial results conference call on Wednesday, August 29, 2018 at 10:00 a.m., Eastern Time. To access the call, please dial (847) 585-4422 or (888) 424-8151 (US toll free) and enter participant PIN code 6638830# approximately ten minutes prior to the start of the call. You will be placed on hold until the event begins. The conference call will also be broadcast over the internet with an accompanying slide presentation. To join the web conference, go to http://web.meetme.net/r.aspx?p=2&a=UTiLPVrenccJZd. Please enter your name, email address and company to join the call. The customer service team can be reached at any time by pressing *0 on your telephone keypad. Prior to the call, the

Huobi Joins GLASS Network and Invests in SharesPost15.8.2018 15:00Pressemelding

Huobi joins network enabling compliant trading of digital securities globally San Francisco, CA, Aug. 15, 2018 (GLOBE NEWSWIRE) -- SharesPost, a leading provider of liquidity solutions to the private growth asset class, has announced that Huobi, China’s largest cryptocurrency and blockchain token exchange and second largest worldwide, has joined the Global Liquidity and Settlement System network (GLASS). When GLASS becomes operational, Huobi will be able to settle secondary trades of digital securities by U.S. investors in compliance with U.S. securities laws. Huobi will also be able to pool its nine million customers’ buy and sell orders with other exchanges using GLASS on a trading pair by trading pair basis. Greg Brogger, Founder and CEO of SharesPost, said: “We are very excited to see GLASS validated by such a highly respected trading platform. It signals the start of the next stage of development in the digital securities market, and we expect it will go a long way to clearing the

SFL Societe Fonciere Lyonnaise: Post Stabilisation Notice15.8.2018 14:02Pressemelding

PARIS, Aug. 15, 2018 (GLOBE NEWSWIRE) -- SFL Societe Fonciere Lyonnaise (EURONEXT PARIS:FLY) TEMP: FLY 15 th August 2018 SFL SOCIETE FONCIERE LYONNAISE Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: SFL SOCIETE FONCIERE LYONNAISE Guarantor (if any): na Aggregate nominal amount: EUR 500,000,000 Description: 1.5% due 29th May 2025 Offer price: 99.199 Stabilising Managers: BNP Paribas, Credit Agricole, HSBC, Natixis, Societe Generale This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS, the news service of the London Stock Exchange.

Constellation Brands to Invest $5 Billion CAD ($4 Billion USD) in Canopy Growth to Establish Transformative Global Position and Alignment15.8.2018 12:30Pressemelding

Expands Strategic Partnership to Accelerate Canopy Growth’s Global Expansion Plans in Rapidly-Growing Medical and Recreational Cannabis Markets VICTOR, N.Y. and SMITHS FALLS, Ontario, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Constellation Brands (NYSE: STZ and STZ.B), a leading beverage alcohol company, and Canopy Growth Corporation (Canopy Growth) (TSX: WEED, NYSE: CGC), a leading diversified cannabis company (together, the “Companies”), today announced a significant expansion of their strategic partnership to position Canopy Growth as the global leader in cannabis production, branding, intellectual property and retailing. Constellation Brands will increase its ownership interest in Canopy Growth by acquiring 104.5 million shares directly from Canopy Growth, thereby achieving approximately 38 percent ownership when assuming exercise of the existing Constellation warrants. Constellation Brands is acquiring the new shares at a price of C$48.60 per share, which is a 37.9 percent premium to Cano

Atico Reports Consolidated Financial Results for the Second Quarter of 201814.8.2018 22:30Pressemelding

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended June 30, 2018, posting a net income of $2.8 million. Fernando E. Ganoza, CEO and Director, commented, "We are pleased to report a strong second quarter and first half of the year. The Company showed improvements in earnings and working capital over the same period last year while remaining on schedule to fully repay the senior debt facility during this fiscal year. Mr. Ganoza continued, "For the second half of this year, we will continue focusing on cost control initiatives to reduce operating costs while also advancing on our regional and underground exploration drill programs." Second Quarter Financial Highlights Net income for the three months ended June 30, 2018 (“Q2-2018”) amounted to $2.8 million, compared with $0.6 m

2018 Online Journalism Awards finalists and James Foley Award recipient announced14.8.2018 19:29Pressemelding

WASHINGTON, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Finalists for the 2018 Online Journalism Awards, representing a wide range of local and international media, nonprofit, public, academic and emerging technology organizations, were announced today by the Online News Association. Thirteen of the awards come with $58,500 in prize money, courtesy of John S. and James L. Knight Foundation, the Gannett Foundation , the University of Florida College of Journalism and Communications and Journalism 360. These awards honor data journalism, visual digital storytelling, investigative journalism, immersive storytelling, public service, technical innovation, student journalism and general excellence. This year’s awards introduced a new category for Excellence in Collaboration and Partnerships, honoring newsrooms and companies who formed innovative partnerships or collaborations to cover a topic or story with a digital focus. In addition, the General Excellence category now has a micro size group for new

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom